Is Precigen, Inc. on the Verge of Breakeven?
ByAinvest
Tuesday, Sep 23, 2025 6:55 am ET1min read
PGEN--
Precigen, Inc. is a biopharmaceutical company with a market cap of $1.1b. Analysts expect the company to breakeven around 2 years from now, with a projected profit of $93m in 2027. To achieve this, the company must grow 69% year-on-year, on average. The company has negative equity on its balance sheet, but this is not uncommon in the biotech industry.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet